Role of the Tumor Microenvironment in Aggressive Meningiomas

NCT05821790 | Unknown

• 1 other identifier: APHP230289
• Study Type: observational
• Target: 40
• Locations: 0 countries
• Sites: N/A

Brief Summary

Meningiomas are the most common primary tumors of the central nervous system in adults. High-grade forms have a high frequency of neurofibromatosis 2 (NF2) mutations and represent 25% of meningiomas, with multiple recurrences associated with morbidity and reduced survival without medical options, including immunotherapy. The meninges play a key role in neuro-immune communication through the diversity of their immune cells and the presence of meningeal lymphatic vessels (MLV). Recent data, including from our team, shows frequent infiltration of lymphocytes and myeloid cells specific to benign meningiomas. Our hypothesis is that the immune microenvironment composed of meningeal immune cells and MLVs regulates the malignant histological progression of NF2-mutated meningiomas and their immune surveillance evasion behavior This study aims to characterize the different cellular populations of the meningioma microenvironment. We will describe the exact participation of immune and vascular cell populations in the initiation and progression of meningioma, using MRI imaging and surgical biopsies of the dura mater and meningioma in patients undergoing neurosurgery for meningioma resection.

Conditions

Meningioma

Keywords

meningioma; meningeal lymphatic vessels; NF2; meningeal micro-environment; immune cells; neurosurgery

Outcome Measures

Primary Outcomes (1)

• Cellular phenotypes and their interactions in the tissue microenvironment

  Characterized by combining different techniques and analysis systems (RNA-seq, RNAScope, Hyperion, Hyperion immunostaining) using samples from various grades of meningiomas and associated dura mater

  one day

Secondary Outcomes (5)

• Expressed genes in meningioma

  one day

• cell types and spatial distribution

  One day

• Visualization of interrelations in the spatial context

  One day

• 3D protein expression

  One day

• Three-dimensional reconstruction

  One day

Study Arms (1)

patients treated for meningioma

Samples required for the study will be obtained from surgical waste of patients who underwent meningioma resection.

Other: Surgical waste and Data collect

Interventions

Surgical waste and Data collect OTHER

Samples required for the study will be obtained from surgical waste of patients who underwent meningioma resection. Data necessary for the study will be collected from the patient's medical records, MRI examinations, and data specific to the characteristics of the surgical waste.

patients treated for meningioma

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients who underwent surgery for the resection of a meningioma

You may qualify if:

• Patients who underwent surgery for the resection of a meningioma.
• Patients with meningiomas located at the convexity and parasagittal regions.
• Patients aged 18 years or older.
• Patients who were informed of the study and did not express opposition to their participation.

You may not qualify if:

• Individuals under legal protection (guardianship, trusteeship) safeguarded by justice

Sponsors & Collaborators

• Assistance Publique - Hôpitaux de Paris: lead
• Paris Brain Institute: collaborator
• Gustave Roussy, Cancer Campus, Grand Paris: collaborator

MeSH Terms

Conditions

Meningioma

Condition Hierarchy (Ancestors)

Neoplasms, Nerve Tissue; Neoplasms by Histologic Type; Neoplasms; Neoplasms, Vascular Tissue; Meningeal Neoplasms; Central Nervous System Neoplasms; Nervous System Neoplasms; Neoplasms by Site; Nervous System Diseases

Study Officials

• Michel KALAMARIDES, MD

  APHP

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Michel KALAMARIDES, MD

CONTACT

1 42 16 31 12; michel.kalamarides@aphp.fr

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 7, 2023
• First Posted: April 20, 2023
• Study Start: May 1, 2023
• Primary Completion: May 1, 2024
• Study Completion: May 1, 2024
• Last Updated: April 20, 2023

Record last verified: 2023-04

Data Sharing

• IPD Sharing: Will not share